2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1018

Methodology Of Determining An Appropriate Look-Back Period To Identify Autoimmune Rheumatic Disease In a Study Of Post-Myocardial Infarction Mortality
Abstract Number: 2181

Methotrexate and Infliximab With Or Without Zoledronic Acid Improve Disease Activity and Prevent Damage Progression In Chronic Nonbacterial Osteomyelitis
Abstract Number: 2688

Methotrexate Dose Has Minimal Effects On Methotrexate-Related Toxicity In Patients With Early Rheumatoid Arthritis Treated In Combination With Adalimumab – Results Of Concerto Trial
Abstract Number: 797

Methotrexate Exposure Assessment In Routine Clinical Rheumatology Practice: Effect Of Dosing and Route Of Administration On Polyglutamate Levels
Abstract Number: 1317

Methotrexate Optimization (ie introduction during the first 3 months and with dose escalation at 6 months at least at 20mg/w or 0.3mg/kg/w) Is Associated With Better Clinical Outcomes In Daily Practice: Results From The Espoir Cohort
Abstract Number: 792

Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients
Abstract Number: 1640

Methotrexate Treatment Affects Effector, But Not Regulatory T Cells in Juvenile Idiopathic Arthritis
Abstract Number: 482

Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Abstract Number: 1108

Methylphenidate Improves Concentration, Energy and Mood In Fibromyalgia
Abstract Number: 2039

Micro and Nanoparticles As Possible Causative-Prognostic Co-Factors Of Mixed Cryoglobulinemia Syndrome
Abstract Number: 148

Microarray Analysis Of Synovial Specimen of Early Human (CHECK) and Experimental Osteoarthritis to Identify Pathways and Processes Associated with Pathology
Abstract Number: 875

Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial
Abstract Number: 1161

Microrna-155 As a Proinflammatory Regulator via SHIP-1 Down-Regulation In Acute Gouty Arthritis
Abstract Number: 2738

Microrna-Mediated Regulation Explains Allelic Risk Of TLR7 Variant Predisposing To Systemic Lupus Erythematosis
Abstract Number: 2595

Microvascular Abnormalities In Patients With Early Systemic Sclerosis: Less Severe Morphological Changes Compared To Patients With Definite Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].